ArticleHuman cell2026
CDH2 marks a fibroblast-associated stromal cell state in pancreatic ductal adenocarcinoma.
Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cadherin-2 (CDH2) has been implicated in angiogenesis-related tumor biology, but its microenvironmental significance remains unclear. To clarify the role of CDH2 in a biologically informative setting, we used a two-round site-selection strategy and identified pancreatic ductal adenocarcinoma (PDAC) as the final study context. Integrative single-cell, spatial, and regulatory analyses were then performed to define the cellular localization and biological meaning of CDH2 in the PDAC microenvironment. CDH2 was reproducibly localized to a fibroblast-associated stromal compartment rather than to a broadly endothelial compartment. Within fibroblasts, CDH2-positive cells were enriched for extracellular matrix remodeling, mesenchymal activation, wound-healing, angiogenesis-related, and TGF-beta-associated programs, supporting a coherent stromal remodeling state. Additional cancer-associated fibroblast (CAF) subtype signature analysis indicated that this state preferentially overlapped with a myofibroblastic CAF-like (myCAF-like)/extracellular matrix-remodeling CAF-like program rather than a dominant inflammatory or antigen-presenting CAF-like program. Communication analysis further showed that CDH2-positive fibroblasts occupied a primarily inter-compartmental, sender-dominant, extracellular matrix-centered signaling niche characterized by prominent collagen-, fibronectin-, and laminin-related interactions with stromal, malignant, myeloid, and endothelial-associated compartments. Spatial transcriptomic mapping supported tissue-level concordance between the CDH2-associated fibroblast state and an extracellular matrix-centered stromal program. Regulatory and counterfactual attenuation analyses further implicated candidate upstream regulators, including RUNX2, SMAD3, and TCF21. Together, these findings indicate that, in PDAC, CDH2 marks a fibroblast-associated CAF-like stromal cell state linked to extracellular matrix remodeling rather than to a directly vascular-centered program.
Indexed as
Identifiers
42437806What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.